| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000042136 |
| Receipt No. | R000048066 |
| Scientific Title | Simple MAGE |
| Date of disclosure of the study information | 2020/10/16 |
| Last modified on | 2022/11/18 (Ver. 2) |
| Basic information | ||
| Public title | Simple MAGE | |
| Acronym | Simple MAGE | |
| Scientific Title | Simple MAGE | |
| Scientific Title:Acronym | Simple MAGE | |
| Region |
|
|
| Condition | ||
| Condition | type 2 diabetes | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To propose a metric which is comparable to 24-h MAGE (Simple MAGE) where synchronize automatic calculation in plural patients can be performed using a software which can be used by anyone like Microsoft Excel. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Correlation between predicted MAGE and SD |
| Key secondary outcomes | (delta - mean of delta)-square for MAGE derived from SD and simple MAGE |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with type 2 diabetes whose 24-h glucose levels were measured continuously using CGM. | |||
| Key exclusion criteria | judged to be unsuitable for participation for medical reasons | |||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Inuyama Chuo General Hospital | ||||||
| Division name | Diabetes | ||||||
| Zip code | 484-8511 | ||||||
| Address | 6, Futagozuka, Goromaru, Inuyama-city, Aichi, Japan. | ||||||
| TEL | 0568-62-8111 | ||||||
| souichi19811225@yahoo.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Inuyama Chuo General Hospital | ||||||
| Division name | Diabetes | ||||||
| Zip code | 484-8511 | ||||||
| Address | 6, Futagozuka, Goromaru, Inuyama-city, Aichi, Japan. | ||||||
| TEL | 0568-62-8111 | ||||||
| Homepage URL | |||||||
| souichi19811225@yahoo.co.jp | |||||||
| Sponsor | |
| Institute | Inuyama Chuo General Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Inuyama Chuo General Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Inuyama Chuo General Hospital |
| Address | 6, Futagozuka, Goromaru, Inuyama-city, Aichi, Japan. |
| Tel | 0568-62-8111 |
| souichi19811225@yahoo.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | This is a cross-sectional study. We investigate 24-h glucose levels (00:00-24:00 on day 2) measured continuously using continuous glucose monitor (CGM: iPro2) in 100 patients with type 2 diabetes. Based on the reports where the values of MAGE were 2.4 times of that of SD, MAGE derived from SD and simple MAGE (both are abbreviated as predicted MAGE) are proposed.
Based on the way of thinking unbiased dispersion, deviations of differences between MAGE and predicted MAGE (delta = MAGE - predicted MAGE) from mean are defined as (delta - mean of delta)-square. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048066 |